Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Is mycophenolate more than just an immunosuppressant?--An overview Iyer A; Brown LIndian J Biochem Biophys 2009[Feb]; 46 (1): 25-30The development of immunosuppressant compounds, such as cyclosporine and tacrolimus was crucial to the success of transplant surgery and for treatment of autoimmune diseases. However, immunosuppressant therapy may increase the concentrations of reactive oxygen species (ROS), inducing oxidative damage such as an increased vascular damage. The major source of ROS in the vascular endothelial cells is NADPH oxidase. The subunit structure and function of this enzyme complex in vascular cells differs from that in phagocytic leucocytes. The enzyme subunits Nox1, Nox2 and Nox4 are only found in vascular cells. The GTP-dependent protein subunit Rac 1 needs to be activated for this enzyme to function. Inhibiting this protein subunit should reduce NADPH oxidase-induced oxidative stress. In the cardiovascular system, oxidative stress is observed as hypertension, hypertrophy, fibrosis, conduction abnormalities and endothelial dysfunction, as well as cardiac allograft vasculopathy in transplant patients. In contrast to cyclosporine and tacrolimus, the immunosuppressant mycophenolate inhibits the Rac 1 subunit thus inhibiting NADPH oxidase in the vasculature. This may reduce oxidative stress, prevent the development of cardiac allograft vasculopathy, decrease the deterioration of vascular function and improve cardiovascular function chronically in transplant patients. This overview discusses whether this antioxidant immunosuppressive property could translate into a more general protective role for mycophenolate in the prevention of cardiovascular disease.|Animals[MESH]|Antioxidants/*pharmacology/therapeutic use[MESH]|Blood Vessels/drug effects/physiology/transplantation[MESH]|Calcineurin Inhibitors[MESH]|Cardiovascular Diseases/drug therapy/physiopathology/prevention & control[MESH]|Cardiovascular System/drug effects/physiopathology[MESH]|Cyclosporine/metabolism/pharmacology[MESH]|Endothelial Cells/drug effects/metabolism[MESH]|Heart Transplantation[MESH]|Humans[MESH]|Immunosuppressive Agents/*pharmacology/therapeutic use[MESH]|Mycophenolic Acid/*pharmacology/therapeutic use[MESH]|NADPH Oxidases/*antagonists & inhibitors/metabolism[MESH]|Oxidative Stress/*drug effects[MESH]|Reactive Oxygen Species/metabolism[MESH]|Tacrolimus/pharmacology[MESH]|rac1 GTP-Binding Protein/*antagonists & inhibitors/metabolism[MESH] |
